A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- RANDOMIZED · SEQUENTIAL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 25
- Population
- ALL · 50 Years
- Duration
- 2015-07-22 to 2016-05-20
- Intervention
- LMG324; Ranibizumab 0.5 mg; Sham
- Comparator
- Lucentis + sham
- Outcomes measured
- Mean change from baseline in best corrected visual acuity (BCVA) at Day 85 — Baseline, Day 85; Percentage of LMG324-treated subjects with no identified SoC treatment need up to and including Day 85 — Up to Day 85; Best Corrected Visual Acuity (BCVA) — Up to Day 169; Central subfield thickness total (CSFTtot) — Up to Day 169; Central subfield thickness neuro-retina (CFSTnr) — Up to Day 169; Lesion thickness — Up to Day 169; Subretinal fluid with foveal involvement (SRFfi) thickness — Up to Day 169; Retinal pigment epithelial detachment with foveal involvement (PEDfi) thickness — Up to Day 169; Area of lesion (associated with CNV) — Up to Day 169; Area of CNV within a lesion — Up to Day 169; Area under the plasma concentration-time curve from time zero to infinity (AUCinf) — Up to Day 169; Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUCla…; Area under the plasma concentration-time curve from time zero to time 't' where t is a defined time point after adminis…; Maximum observed maximum plasma concentration (Cmax) — Up to Day 169; Time to reach the maximum observed plasma concentration (Tmax) — Up to Day 169; Observed maximum plasma concentration following drug administration, by dose (Cmax/D) — Up to Day 169; Area under the plasma concentration-time curve divided by dose (AUC/D) — Up to Day 169; Frequency of subjects with anti-LMG324 antibodies — Up to Day 169
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.